ISRCTN13459412已完成不适用
An open-label study followed by a double-blind randomised comparison of the effect of sedation versus melatonin combined with sedation in children undergoing magnetic resonance imaging (MRI)
Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)0 个研究点目标入组 0 人开始时间: 2004年9月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Children undergoing MRI
排除标准
- •Not provided at time of registration
研究者
相似试验
招募中
2 期
Study of Koflet in CoughCTRI/2023/01/049070Himalaya Wellness Company
尚未招募
2 期
Ayurveda management of ARTAVA KSHAYA w.s.r to PCOSCTRI/2024/05/067664DrBharathi K S
招募中
1 期
A clinical study to test the safety and efficacy of GB1211 in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).Study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).EUCTR2021-003189-11-ITGalecto Biotech AB77
进行中（未招募）
1 期
The purpose of this study is to evaluate a drug (LUM001 also known as SHP625) that may help treat the liver and control itching in Alagille Syndrome. In the Optional Follow-up Treatment Period (after Week 48), all eligible children treated in the LUM001-304 study will be offered to continue the study drug treatment until the subjects are eligible to enter another LUM001 study or LUM001 is available commercially, or the sponsorstops the program or development in this indication.Alagille syndrome (ALGS) is an autosomal dominant with variable penetration genetic multisystem disorder. The clinical diagnosis is based on the presence of intrahepatic bile duct paucity on liver biopsy in association with at least three of the major clinical features: chronic cholestasis, cardiac disease, skeletal abnormalities, ocular abnormalities and characteristic facial features.MedDRA version: 20.0Level: PTClassification code 10053870Term: Alagille syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-005373-43-GBMirum Pharmaceuticals, Inc.30
进行中（未招募）
1 期
The purpose of this study is to evaluate a drug (LUM001) that may help treat the liver and control itching in Alagille Syndrome. In this study, all children who are eligible to enrol will take study drug for 18 weeks, followed by a 4 week period where they will either take LUM001 or placebo. After this 4 week period, all patients will go back on active study drug treatment for the remaining 26 weeks.EUCTR2013-005373-43-FRumena Pharmaceuticals Inc30